Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Surveys and Questionnaires 16Bevacizumab 14Cisplatin 12Blood Specimen Collection 11Drug Therapy 10Standard of Care 9Nivolumab 9Gemcitabine 9Cetuximab 7pembrolizumab 6Specimen Handling 6S 1 (combination) 6Endoscopic Mucosal Resection 6Cyclophosphamide 6atezolizumab 5Sunitinib 5Radiotherapy 5Folfox protocol 5Educational Status 5Docetaxel 5fludarabine 4aldesleukin 4Radiosurgery 4Pemetrexed 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × patritumab deruxtecan × Gastrointestinal × Clear all
NCT06596694 2026-06-01

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
180 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡